Thomas E. Lew

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia

Piers Blombery, Mary Ann Anderson, Jianan Gong et al. · Cancer Discovery · 2018 · 412 citations

Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax

Mary Ann Anderson, Constantine S. Tam, Thomas E. Lew et al. · Blood · 2017 · 174 citations

Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance

Piers Blombery, Ella R. Thompson, Thomas E. Lew et al. · Blood Advances · 2022 · 89 citations · Full text

Hematological Malignancy, Btk Leu528trp Mutation, Oncology +15

BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax

Victor S. Lin, Thomas E. Lew, Sasanka M. Handunnetti et al. · Blood · 2020 · 84 citations · Full text

Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy

Rachel Thijssen, Luyi Tian, Mary Ann Anderson et al. · Blood · 2022 · 81 citations · Full text

Bcl2 Family, Mixed-phenotype Acute Leukemia, Immunology +26